Stroke is a leading cause of death and severe long-term disability with limited treatment available. A research team led by Professor Gong Chen at Jinan University, Guangzhou, China recently reported the first non-human primate study demonstrating successful in vivo neural regeneration from brain internal glial cells for stroke repair. This work was published on Frontiers in Cell and Developmental Biology.
Sleep paralysis — a condition thought to explain a number of mysterious experiences including alleged cases of alien abduction and demonic night-time visits — could be treated using a technique of meditation-relaxation, suggested a pilot study.
Scientists at The Wistar Institute may have discovered a new way of identifying and targeting hidden HIV viral reservoirs during treatment with antiretroviral therapy (ART). These findings were published in Cell Reports and may have translational implications for improving the long-term care of HIV positive people.
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.
Amyotrophic lateral sclerosis, or ALS, is a progressive neurodegenerative disease that leads to the death of nerve cells that control movement, leaving people unable to move and, eventually, to breathe.
New data have shown for the first time that a combination of targeted therapies can improve survival in patients with advanced bowel cancer. Results of the BEACON CRC Phase III trial have shown that triple therapy targeting BRAF mutations in progressive metastatic colorectal tumors significantly improved overall survival and objective response compared to standard care.